tirzepatide hba1c reduction with in people with type 2 diabetes: The contribution of weight loss assessed by a mediation analysis - Vilsbøll - 2025 - Diabetes, Obesity and Metabolism Frontiers | Comparative effectiveness of

3e, Supplementary Table 4)

Practical Takeaways for Patients If youre considering or already using a GLP-1 agonist and have a history of breast cancer, heres a way to think about it: Current data are reassuring No clear evidence of increased breast cancer risk No obvious signal of worse outcomes or recurrence There may be indirect benefits Better weight control Better diabetes management Both are linked to better breast cancer outcomes There are still unknowns No large, breast-cancer-only randomized trials yet Possible signals for pancreatic and thyroid cancer need more research Your situation is unique Your tumor type, treatments, other conditions (like diabetes or heart disease), and medications all matter This is exactly the kind of decision that should be made with your oncologist and primary care team Final Word Right now, the evidence says: GLP-1 agonists appear safe from a breast cancer perspective, both for risk and for recurrence

The SELECT trial demonstrated semaglutide reduces major adverse cardiovascular events by 20% in non-diabetic patients, repositioning GLP-1 drugs as disease-modifying therapies

A., Tipisova, E

Storage: Handling: Keep the pen cap on to protect it from light, and keep it away from the cooling element